TRIOLOGY ACS: No benefit/No harm

Authors

  • Mahmoud Farouk Elmahdy Aswan Heart Centre, Aswan
  • David Antoniucci Careggi Hospital, Florence, Italy

Abstract

[first paragraph of article]

Potent and consistent P2Y12 receptor inhibition is associated with reduced risk of atherothrombotic events in patients presenting with acute coronary syndromes (ACS), but with inevitable increased risk of bleeding as demonstrated in TRITON and PLATO trials – a finding that is especially pertinent to the treatment of medically managed NSTE ACS patients, who typical have a greater burden of comorbidities that predispose to bleeding.

Given the significant proportion of non-ST elevation myocardial infarction (NSTE) ACS patients managed medically worldwide and the need to mitigate both ischemic and bleeding risks in this vulnerable, high-risk population, novel clinical trials are needed. 

Downloads

Published

2017-05-29

Issue

Vol. 2013 No. 2 (2013)

Section

Lessons from the trials

License

This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.